The pleiotropic protein known as transforming growth factor-beta (TGF-) is a member of a superfamily that controls several cellular processes, including growth, development, and differentiation. The Smad proteins, which are the intracellular TGF-beta signaling effectors, are activated by receptors and move into the nucleus where they control transcription. Although this pathway is fundamentally straightforward, cooperation with sequence-specific transcription factors, combinatorial interactions in the heteromeric receptor and Smad complexes, receptor-interacting and Smad-interacting proteins, and other factors enable significant versatility and diversity of TGF-beta family responses. Smad activation and function are further regulated by other signaling pathways.
Additionally, TGF-beta receptors activate Smad-independent pathways that enable Smad-independent TGF-beta responses in addition to regulating Smad signaling. Abnormal TGF- signaling has been linked to a number of illnesses, including cancer, cardiovascular disease, and fibrosis. Consequently, it is acknowledged that the TGF-signaling pathway is a potential drug target.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V93041 | (+)-ITD-1 | 1409968-46-2 | (+)-ITD-1 is an inhibitor of TGF-β and can inhibit TGF-β2 with IC50 of 0.46 μM. |
|
V67548 | 3,3-Dimethyl-1-butanol (DMB; Neohexanol) | 624-95-3 | 3,3-Dimethyl-1-butanol (DMB) is an orally bioavailable inhibitor of trimethylamine (TMA) and trimethylamine-N-oxide (TMAO). |
|
V67546 | 3,7-DMF | 20950-52-1 | 3,7-DMF is an orally bioavailable inhibitor of TGF-β1-induced HSC activation. |
|
V93191 | ALK5-IN-83 | ALK5-IN-83 (Compound 13b) is an ALK5 inhibitor with IC50 of 0.13 μM. | |
|
V97307 | CBT-295 | CBT-295 is an oral autotaxin (ATX) inhibitor. | |
|
V67562 | Dalbergioidin | 30368-42-4 | Dalbergioidin is a well-known anthocyanin that improves doxorubicin-induced renal fibrosis by inhibiting the TGF-β signaling pathway. |
|
V97786 | DCN1-IN-2 | 2543578-57-8 | DCN1-IN-2 is a DCN1 inhibitor with IC50 of 2.96 nM. |
|
V67547 | DT-6 | 2414315-95-8 | DT-6 is a potent inhibitor of TGF-β1. |
|
V67561 | Hydrochlorothiazid-d2 (HCTZ-d2) | 1219798-89-6 | Hydrochlorothiazid-d2 is the deuterated form of Hydrochlorothiazide. |
|
V67563 | Hydrochlorothiazide-13C6 (HCTZ-13C6) | 1261396-79-5 | Hydrochlorothiazide-13C6 is 13C (carbon 13) labelled Hydrochlorothiazide. |
|
V94945 | Klotho-derived peptide 1 hydrochloride | Klotho-derived peptide 1 (human KP1) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced Smad2/3 and mitogen-activated protein kinase (MAPK) activation, and exhibits antifibrotic and renal protective effects in mouse models. | |
|
V3250 | LDN-193189 2HCl | 1435934-00-1 | LDN193189 2HCl is the dihydrochloride salt ofLDN193189, which is a highly potent andselective small molecule inhibitor of the BMP (bone morphogenetic protein) signaling pathway. |
|
V67553 | Luspatercept (ACE-536; luspatercept–aamt) | 1373715-00-4 | Luspatercept (ACE-536) is a recombinantly modified ActRIIB fusion protein that binds to transforming growth factor beta superfamily ligands. |
|
V67566 | Myristoyl tetrapeptide-12 | 959610-24-3 | Myristoyl tetrapeptide-12 directly activates SMAD2 and induces the association of SMAD3 with DNA. |
|
V67565 | Nisevokitug (NIS-793) | 2649854-92-0 | Nisevokitug (NIS-793) is a human IgG2λ antibody targeting TGF-beta (TGFB1/TGFB2). |
|
V98087 | P17 Peptide | 846546-36-9 | P17 Peptide is a human TGF-β1 inhibitory peptide. |
|
V67551 | SIS3 free base | 521985-36-4 | SIS3 free base is a potent and specific inhibitor of Smad3 phosphorylation. |
|
V2956 | SIS3 HCl | 521984-48-5 | SIS3 HCl is a potent and selective inhibitor of Smad3 which is a receptor-regulated intracellular protein that functions downstream of TGF-β and activin receptors and mediates their signaling, playing a role in cell proliferation, differentiation, apoptosis and formation of extracellular matrix. |
|
V4080 | SRI-011381 | 1629138-41-5 | SRI-011381 (SRI011381) is a novel and potent agonist of the TGF-beta signaling pathway with the potential for treatment of Alzheimers disease. |
|
V67545 | SRI-011381 hydrochloride | 2070014-88-7 | SRI-011381 HCl is an orally bioavailable activator of the TGF-β signaling pathway with neuro-protective (neuro-protection) effects. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
